318 related articles for article (PubMed ID: 29384099)
1. [Which future for B lymphocytes infiltrating solid tumors: prognostic biomarker and/or therapeutic target?].
Kaplon H; Dieu-Nosjean MC
Med Sci (Paris); 2018 Jan; 34(1):72-78. PubMed ID: 29384099
[TBL] [Abstract][Full Text] [Related]
2. [Immunotherapy and targeted therapy, a promising combination to fight cancer].
Andrieu N; Bendriss-Vermare N
Med Sci (Paris); 2018 Oct; 34(10):872-875. PubMed ID: 30451657
[No Abstract] [Full Text] [Related]
3. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
[TBL] [Abstract][Full Text] [Related]
4. Immune signature of tumor-infiltrating immune cells predicts the prognosis and therapeutic effects in squamous cell carcinoma.
Che Y; Luo Z; Zhang C; Sun N; Gao S; He J
Int Immunopharmacol; 2020 Oct; 87():106802. PubMed ID: 32745903
[TBL] [Abstract][Full Text] [Related]
5. Immuno-oncology-101: overview of major concepts and translational perspectives.
Allard B; Aspeslagh S; Garaud S; Dupont FA; Solinas C; Kok M; Routy B; Sotiriou C; Stagg J; Buisseret L
Semin Cancer Biol; 2018 Oct; 52(Pt 2):1-11. PubMed ID: 29428479
[TBL] [Abstract][Full Text] [Related]
6. SITC 2018 workshop report: Immuno-Oncology Biomarkers: State of the Art.
Butterfield LH; Disis ML; Fox BA; Kaufman DR; Khleif SN; Wang E;
J Immunother Cancer; 2018 Dec; 6(1):138. PubMed ID: 30514399
[TBL] [Abstract][Full Text] [Related]
7. Exosomes Function in Tumor Immune Microenvironment.
Huang Y; Liu K; Li Q; Yao Y; Wang Y
Adv Exp Med Biol; 2018; 1056():109-122. PubMed ID: 29754177
[TBL] [Abstract][Full Text] [Related]
8. [New frontiers in the fight against cancer].
Chiossone L; Vivier E
Biol Aujourdhui; 2018; 212(3-4):61-67. PubMed ID: 30973133
[TBL] [Abstract][Full Text] [Related]
9. [Immunotherapy in lung cancer: New concepts].
Goubet AG; Livartowski A; Romano E
Rev Mal Respir; 2018 Jun; 35(6):642-651. PubMed ID: 29941206
[TBL] [Abstract][Full Text] [Related]
10. The Challenge for Development of Valuable Immuno-oncology Biomarkers.
Mehnert JM; Monjazeb AM; Beerthuijzen JMT; Collyar D; Rubinstein L; Harris LN
Clin Cancer Res; 2017 Sep; 23(17):4970-4979. PubMed ID: 28864725
[TBL] [Abstract][Full Text] [Related]
11. First advanced course on biomarkers in molecular and immuno-oncology in the Middle East.
Moujaess E; Khoury M; Zouein J; Eid JB; Mohty R; Kourie HR
Future Oncol; 2021 Aug; 17(22):2831-2834. PubMed ID: 34148366
[TBL] [Abstract][Full Text] [Related]
12. [Tim-3: a novel biomarker and therapeutic target in oncology].
Granier C; Gey A; Dariane C; Mejean A; Timsit MO; Blanc C; Verkarre V; Radulescu C; Fabre E; Vano Y; Oudard S; Badoual C; Tartour É
Med Sci (Paris); 2018 Mar; 34(3):231-237. PubMed ID: 29547109
[TBL] [Abstract][Full Text] [Related]
13. Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy.
Gnjatic S; Bronte V; Brunet LR; Butler MO; Disis ML; Galon J; Hakansson LG; Hanks BA; Karanikas V; Khleif SN; Kirkwood JM; Miller LD; Schendel DJ; Tanneau I; Wigginton JM; Butterfield LH
J Immunother Cancer; 2017; 5():44. PubMed ID: 28515944
[TBL] [Abstract][Full Text] [Related]
14. Immuno-pharmacodynamics for evaluating mechanism of action and developing immunotherapy combinations.
Parchment RE; Voth AR; Doroshow JH; Berzofsky JA
Semin Oncol; 2016 Aug; 43(4):501-13. PubMed ID: 27663482
[TBL] [Abstract][Full Text] [Related]
15. Immune Landscape in Tumor Microenvironment: Implications for Biomarker Development and Immunotherapy.
Pérez-Romero K; Rodríguez RM; Amedei A; Barceló-Coblijn G; Lopez DH
Int J Mol Sci; 2020 Aug; 21(15):. PubMed ID: 32752264
[TBL] [Abstract][Full Text] [Related]
16. Priming the tumor immune microenvironment with chemo(radio)therapy: A systematic review across tumor types.
van den Ende T; van den Boorn HG; Hoonhout NM; van Etten-Jamaludin FS; Meijer SL; Derks S; de Gruijl TD; Bijlsma MF; van Oijen MGH; van Laarhoven HWM
Biochim Biophys Acta Rev Cancer; 2020 Aug; 1874(1):188386. PubMed ID: 32540465
[TBL] [Abstract][Full Text] [Related]
17. Classification of Advanced Human Cancers Based on Tumor Immunity in the MicroEnvironment (TIME) for Cancer Immunotherapy.
Zhang Y; Chen L
JAMA Oncol; 2016 Nov; 2(11):1403-1404. PubMed ID: 27490017
[No Abstract] [Full Text] [Related]
18. The B-side of Cancer Immunity: The Underrated Tune.
Largeot A; Pagano G; Gonder S; Moussay E; Paggetti J
Cells; 2019 May; 8(5):. PubMed ID: 31086070
[TBL] [Abstract][Full Text] [Related]
19. The Immune Landscape in Women Cancers.
Timperi E; Vissio E; Marchiò C; Romano E
Cancer Treat Res; 2020; 180():215-249. PubMed ID: 32215872
[TBL] [Abstract][Full Text] [Related]
20. Biomarkers for Immunotherapy: Current Developments and Challenges.
Spencer KR; Wang J; Silk AW; Ganesan S; Kaufman HL; Mehnert JM
Am Soc Clin Oncol Educ Book; 2016; 35():e493-503. PubMed ID: 27249758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
